Raphael Clynes, M.D., Ph.D., has been appointed vice president of translational biology, Xencor. Dr. Clynes fills a new position created to study the biological mechanisms of XmAb antibody drug candidates, particularly in immuno-oncology. “It is with great pleasure that we welcome Raphael, a recognized leader in immunotherapy research, to Xencor,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “His experience in drug discovery and development...